ARWR Arrowhead Pharmaceuticals
- 23.290
- -0.490-2.06%
Arrowhead Pharmaceuticals News
Arrowhead Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(10.01%)
Arrowhead Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hamilton James C
Arrowhead Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Arrowhead Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lu Hongbo
Arrowhead Pharmaceuticals | 8-K: Current report
Arrowhead Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Lu Hongbo
Arrowhead Pharmaceuticals | 8-K/A: Current report (Amendment)
Arrowhead Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Myszkowski Kenneth Allen
Arrowhead Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Arrowhead Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Arrowhead Pharmaceuticals | DEFA14A: Others
Arrowhead Pharmaceuticals | 8-K: Current report
Arrowhead Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.93%)
Arrowhead Pharmaceuticals | 10-Q: Quarterly report
Arrowhead Pharmaceuticals | 8-K: Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Arrowhead Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Anzalone Christopher Richard
Arrowhead Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Arrowhead Pharmaceuticals | ARS: Annual Report to Security Holders
Arrowhead Pharmaceuticals | DEF 14A: Definitive information statements
Arrowhead Pharmaceuticals | DEFA14A: Others
Analysis
Price Target
No Data
